Medtronic Inc (MDT.N)

MDT.N on New York Stock Exchange

55.49USD
1 Aug 2013
Price Change (% chg)

$0.25 (+0.45%)
Prev Close
$55.24
Open
$55.34
Day's High
$55.61
Day's Low
$55.23
Volume
1,755,268
Avg. Vol
1,563,962
52-wk High
$55.89
52-wk Low
$38.54

MDT.N

Chart for MDT.N

About

Medtronic, Inc. (Medtronic) is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac... (more)

Overall

Beta: 1.00
Market Cap (Mil.): $55,654.34
Shares Outstanding (Mil.): 1,007.50
Dividend: 0.28
Yield (%): 2.03

Financials

  MDT.N Industry Sector
P/E (TTM): 16.36 27.50 37.76
EPS (TTM): 3.38 -- --
ROI: 11.99 9.26 18.76
ROE: 19.38 12.54 19.59
Search Stocks

UPDATE 1-Medtronic loses heart valve patent fight in Germany

July 12 - A German court ruled against Medtronic Inc in the latest round of its patent fight with Edwards Lifesciences on Friday, judging the U.S. medical device maker's transcatheter heart valve technology infringes a patent owned by Edwards.

12 Jul 2013

Medtronic loses heart valve patent fight in Germany

July 12 - A German court ruled against Medtronic Inc in the latest round of its patent fight with Edwards Lifesciences on Friday, judging the U.S. medical device maker's heart valve technology infringes a patent owned by Edwards.

12 Jul 2013

Medtronic takes 'first step' toward U.S. sale of artificial pancreas

CHICAGO - Type 1 diabetics, who run the risk of dangerously low blood sugar, may be a step closer to getting help from a crude artificial pancreas device that can read blood sugar levels and automatically turn off the flow of insulin after a clinical trial showed the device is safe.

22 Jun 2013

Medtronic takes '1st step' toward U.S. sale of artificial pancreas

CHICAGO, June 22 - Type 1 diabetics, who run the risk of dangerously low blood sugar, may be a step closer to getting help from a crude artificial pancreas device that can read blood sugar levels and automatically turn off the flow of insulin after a clinical trial showed the device is safe.

22 Jun 2013

Medtronic profit beats estimates as international sales jump

- Medical device maker Medtronic Inc reported a better-than-expected quarterly profit, driven by strong international sales, a lower tax rate and demand for new heart stent products, sending its shares up 5 percent in late-morning trading.

21 May 2013

Medtronic profit beats estimates as international sales jump

May 21 - Medical device maker Medtronic Inc reported a better-than-expected quarterly profit driven by strong international sales.

21 May 2013

Supreme Court agrees to hear Medtronic patent case

WASHINGTON - The U.S. Supreme Court on Monday agreed to hear a patent dispute concerning Medtronic Inc over medical devices it manufactures that give the heart electrical jolts when it fails to pump blood properly.

20 May 2013

UPDATE 1-U.S. Supreme Court agrees to hear Medtronic patent case

WASHINGTON, May 20 - The U.S. Supreme Court on Monday agreed to hear a patent dispute concerning Medtronic Inc over medical devices it manufactures that give the heart electrical jolts when it fails to pump blood properly.

20 May 2013

U.S. Supreme Court agrees to hear Medtronic patent case

WASHINGTON, May 20 - The U.S. Supreme Court on Monday agreed to hear a patent dispute concerning Medtronic Inc over medical devices it manufactures that give the heart electrical jolts when it fails to pump blood properly.

20 May 2013

REFILE-BRIEF-Medtronic says FDA approves longer lengths of Resolute Integrity stent

Feb 25 - Feb 25 - Medtronic Inc : * FDA approves longer lengths of medtronic's resolute integrity stent * FDA approved 34mm,38mm lengths of resolute integrity drug-eluting stent in

25 Feb 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks